CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM
New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing the industry's first quantitative business case for risk-based oversight in clinical development WAYNE, Pa., July 7, 2026 /PRNewswire/ -- CluePoints, provider of leading...
New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing the industry's first quantitative business case for risk-based oversight in clinical development WAYNE, Pa., July 7, 2026 /PRNewswire/ -- CluePoints, provider of leading...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.